8-K: Zeta Global Rebuts Misleading Report, Affirms Financial Integrity After Forensic Review

Zeta Global has released the findings of a forensic review confirming the accuracy of its financial statements and the soundness of its business practices, in response to a recently published report containing false allegations.

Summary

• Zeta Global has completed a forensic review in 2022 and 2023, overseen by its Audit Committee, which found the company's financial statements to be accurate and fairly presented.
• The review, conducted by Latham & Watkins LLP and external forensic accountants, scrutinized Zeta's contractual arrangements as both a vendor and a customer.
• The company is responding to a report containing false claims that was published on November 13, 2024.
• Zeta's internal controls over financial reporting were also deemed effective by the review.
• The company disclosed its cooperation with a federal investigation into Kubient, Inc., a company with which Zeta had a business relationship before its IPO in 2021, but stated that the relationship was not material and ended before the IPO.
• Zeta has authorized a $100 million stock repurchase program and management has been purchasing shares.
• The company has posted a detailed rebuttal on its Investor Relations website to address the false claims.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's strong rebuttal and confirmation of financial integrity, but there is still some concern due to the initial negative report and potential legal risks.

Positives

• The forensic review, conducted by external parties, supports the integrity of Zeta's financial reporting.
• The company's internal controls over financial reporting are deemed effective.
• The $100 million stock repurchase program and management's stock purchases demonstrate confidence in the company's future.
• Zeta has taken a proactive approach to address the false claims by publishing a detailed rebuttal.
• The company has clarified that CAM disclosures are common and do not reflect negatively on the company.

Negatives

• Zeta was the target of a report containing false and misleading claims, which negatively impacted the stock price.
• The company had a business relationship with Kubient, Inc., which was subject to a federal investigation, although Zeta states the relationship was not material and ended before the IPO.

Risks

• The company is facing reputational risk due to the false claims made in the report.
• There is a risk of potential legal action against the publisher of the report.
• The company's stock price may be volatile due to the negative publicity.
• The company is subject to the risks and uncertainties associated with forward-looking statements.

Future Outlook

Zeta Global intends to continue creating long-term shareholder value and demonstrate the strength and resilience of its business model. The company will continue to communicate transparently with its stakeholders and may take legal action against the publisher of the report. The company expects to continue to buy back stock under the repurchase program.

Management Comments

• David Steinberg, Co-Founder, Chairman, and CEO of Zeta, stated that the forensic review found the company's practices sound and financial statements accurate.
• Robert Niehaus, Chair of Zeta's Audit Committee, said that the findings should give any objective person confidence in the integrity of Zeta's operations, controls, processes, and financial statements.
• David A. Steinberg stated that the short seller report was filled with highly misleading and objectively false claims and was written with a clear agenda to drive down the value of the stock.

Industry Context

The situation highlights the increasing scrutiny that publicly traded companies face from short sellers and the importance of robust internal controls and transparent communication. The use of forensic reviews to validate financial statements is becoming more common in response to such challenges. The company's response is consistent with industry best practices for addressing such reports.

Comparison to Industry Standards

• The company's use of a forensic review by an external law firm and forensic accountants is a standard practice when responding to allegations of financial misconduct, similar to actions taken by other companies facing similar challenges.
• The disclosure of Critical Audit Matters (CAM) is a common practice for publicly traded companies, as highlighted by the Audit Analytics survey, and Zeta's disclosure is in line with industry norms.
• The company's stock repurchase program is a common strategy used by companies to signal confidence in their business and to potentially increase shareholder value, similar to actions taken by other companies in response to stock price declines.

Legal Proceedings

• Zeta is considering legal action against the publisher of the report containing false claims.

Stakeholder Impact

• Shareholders are impacted by the stock price volatility and the company's response to the false claims.
• Employees may be affected by the reputational risk and potential legal proceedings.
• Customers and suppliers may be reassured by the company's confirmation of its financial integrity.

Next Steps

• Zeta will continue to buy back stock under the repurchase program.
• The company may pursue legal action against the publisher of the false report.
• Zeta will continue to communicate transparently with its stakeholders.

Key Dates

Keywords

forensic review, financial statements, internal controls, stock repurchase, short seller report, misleading claims, audit committee, Kubient, critical audit matters, legal remedies